ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: Annual Revenue Growth Compared

Pharmaceutical Revenue Trends: ACADIA vs. Taro, 2014-2023

__timestampACADIA Pharmaceuticals Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014120000759285000
Thursday, January 1, 201561000862944000
Friday, January 1, 201617331000950751000
Sunday, January 1, 2017124901000879387000
Monday, January 1, 2018223807000661913000
Tuesday, January 1, 2019339076000669893000
Wednesday, January 1, 2020441755000644769000
Friday, January 1, 2021484145000548970000
Saturday, January 1, 2022517235000561347000
Sunday, January 1, 2023726437000572952000
Monday, January 1, 2024629182000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceuticals: Revenue Growth from 2014 to 2023

In the competitive world of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd. have shown contrasting trajectories. ACADIA Pharmaceuticals, starting with a modest revenue in 2014, has seen a remarkable increase, growing by over 6,000% by 2023. This growth highlights their strategic advancements and market penetration. In contrast, Taro Pharmaceutical Industries, with a strong revenue base in 2014, experienced a decline of approximately 25% by 2023. This shift may reflect market challenges or strategic realignments. Notably, the data for 2024 is incomplete, leaving room for speculation on future trends. As these companies navigate the ever-evolving pharmaceutical landscape, their revenue trends offer valuable insights into their market strategies and adaptability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025